https://www.selleckchem.com/products/SB-743921.html BACKGROUND Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients. METHODS Adults aged ≥65 years previously vaccinated with ZVL ≥5 years before (HZ-PreVac, N=215) were group-matched with ZVL-naïve individuals (HZ-NonVac, N=215) and vaccinated with RZV. Glycoprotein E (gE)-specific humoral and cell-mediated immune (CMI) responses and the correlation between them, polyfunctional gE-specific CD4 T-cell responses, safety, and confirmed HZ cases were assessed. RESULTS Through 12 months post-dose 2, anti-gE antibody concentrations, gE-specific CD4 T-cell frequencies and activation marker profiles were similar between groups. Safety outcomes were also similar. No HZ episodes were confirmed. CONCLUSIONS RZV induced strong humoral and polyfunctional CMI responses that persisted above pre-vaccination levels through 1 year post-dose 2 in adults aged ≥65 years irrespective of previous ZVL vaccination. RZV's safety profile was not impacted either. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.We presented an artificial intelligence-based model to predict annual effective dose (AED) value of health workers. Potential factors affecting AED and the results of annual blood tests were collected from 91 radiation workers. Filter-based feature selection strategy revealed that the eight factors plate, red cell distribution width (RDW), educational degree, nonacademic course in radiation protection (hour), working hours per month, department and the number of procedures done per year and work in radiology department or not (0,1) were the most important predictors for AED. The prediction model was developed using a multilayer perceptron neural network and these prediction parameters as inputs. The model provided favorable a